• why us?
  • Case Studies
  • Due diligence on a reverse merger candidate with pipeline of IND-ready compounds


A NASDAQ-listed biotech asked Alacrita to conduct a technical due diligence on a prospect reverse merger candidate. After screening numerous companies, our client identified a strong candidate with a pipeline of IND-ready small molecule compounds with potential applications principally in immuno-oncology. The client requested Alacrita to investigate four of the pipeline candidates in oncology and perform a commercial appraisal of the opportunity and competitiveness of the products.


The due diligence project performed by Alacrita comprised two parallel and related tasks:

  • A technical review of the target data room contents to identify risks, gaps, weaknesses and inconsistencies, commenting specifically on receptor selectivity, pharmacokinetic profile, preclinical toxicology and safety pharmacology

  • A commercial appraisal of the prospects for the molecular class in general, and the target's competitive position versus other pipeline candidates.

A report was then prepared for the client listing our findings for each of the four pipeline candidates.


Due Diligence Consulting

Alacrita has been a dependable due diligence partner for over a decade, bringing both the experience & expertise necessary to help our clients minimize risk, confirm value and make informed decisions.

Contact Us

Reach out today for more information on our due diligence consulting services.

Related Due Diligence Case Studies | View all